Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 17/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 14/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.66 |
| ▸ | DPP4 | P27487 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31441154 | 1.00 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2DPP4 | |
| Hydrochloric Acid SCHEMBL3523556 | 0.98 | SLC6A3 (0.96) | SLC6A3SLC6A4SLC6A2DPP4 | |
| SCHEMBL7888175 | 0.98 | SLC6A3 (0.96) | SLC6A3SLC6A4SLC6A2DPP4 | |
| SCHEMBL2338711 | 0.94 | SLC6A3 (0.89) | SLC6A3SLC6A4SLC6A2DPP4 | |
| Hydrochloric Acid SCHEMBL1687047 | 0.92 | SLC6A3 (0.85) | SLC6A3SLC6A4SLC6A2DPP4 | |
| SCHEMBL1672926 | 0.90 | SLC6A3 (0.81) | SLC6A3SLC6A4SLC6A2DPP4 | |
| Hydrochloric Acid SCHEMBL15757515 | 0.88 | SLC6A3 (0.78) | SLC6A3SLC6A4SLC6A2DPP4 | |
| SCHEMBL5090597 | 0.85 | SLC6A3 (0.73) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL2701343 | 0.81 | SLC6A3 (0.68) | SLC6A3SLC6A4SLC6A2DPP4 | |
| SCHEMBL3485923 | 0.81 | SLC6A3 (0.68) | SLC6A3SLC6A4SLC6A2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556117-B2 | Indole carboxamide derivatives as P2X7 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-01-31 | — | — | US | claimed |
| EP-2935211-B1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-11-09 | — | — | EP | claimed |
| US-20150344425-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-03 | — | — | US | claimed |
| EP-2935211-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2015-10-28 | — | — | EP | claimed |
| WO-2014097140-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2014-06-26 | — | — | WO | claimed |
| US-20120190680-A1 | Heteroaryl Amide Analogues | H. LUNDBECK A/S (DK) | 2012-07-26 | — | — | US | claimed |
| EP-4305026-B1 | ANTI-INFLAMMATORY CARBOXAMIDE DERIVATIVES | BIOMEDCODE HELLAS SA (GR) | 2025-05-07 | — | — | EP | disclosed |
| EP-3402469-B1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | INST NAT SANTE RECH MED (FR) | 2021-01-06 | — | — | EP | disclosed |
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARAMCEUTICALS INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10548980-B2 | P2X7 receptor antagonists for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV) | INSERM (Institut National de la Santé et de la Recherche Médicale (FR) | 2020-02-04 | — | — | US | disclosed |
| US-20190022223-A1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET LA SANTÉ ET DE LA RECHERCHE MÉDICALE) (FR) | 2019-01-24 | — | — | US | disclosed |
| US-9873709-B2 | Triazolopyridine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9868718-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20100190861-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190861-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2010-07-29 | — | — | US | disclosed |
| EP-2178865-A2 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | Lundbeck, H., A/S (DK) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009012482-A2 | 5-MEMBERED HETEROCYCLIC AMIDES AND RELATED COMPOUNDS | H.LUNDBECK A/S (DK) | 2009-01-22 | — | — | WO | disclosed |
| US-20070203111-A1 | Cycloalkylamines as monoamine reuptake inhibitors | SEPRACOR INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203111-A1 | Cycloalkylamines as monoamine reuptake inhibitors | SEPRACOR INC. (US) | 2007-08-30 | — | — | US | disclosed |
| WO-2007081857-A2 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10548980-B2 | P2X7 receptor antagonists for restoring T-cell lymphopoiesis in subjects infected with human immunodeficiency virus (HIV) | P2RX7, P2RX1, P2RX5 | SLC6A3 1944/4885SLC6A4 1392/4885SLC6A2 919/4885 |
| US-20150344425-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | P2RX7, P2RX3, P2RX1 | SLC6A3 537/4885SLC6A4 343/4885SLC6A2 630/4885 |
| US-20070203111-A1 | Cycloalkylamines as monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | SLC6A3 4/4885SLC6A4 5/4885SLC6A2 2/4885 |
| US-20100190861-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | SLC6A3 4/4885SLC6A4 5/4885SLC6A2 2/4885 |
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | SLC6A3 4/4885SLC6A4 5/4885SLC6A2 2/4885 |
| US-20120190680-A1 | Heteroaryl Amide Analogues | P2RX3, P2RX2, ADORA2A | SLC6A3 88/4885SLC6A4 615/4885SLC6A2 203/4885 |
| US-20190022223-A1 | P2X7 RECEPTOR ANTAGONISTS FOR RESTORING T-CELL LYMPHOPOIESIS IN SUBJECTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) | P2RX7, P2RX1, P2RX5 | SLC6A3 1944/4885SLC6A4 1392/4885SLC6A2 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.